Kuros Biosciences (VTX:KURN) H1 2024 Results

Key financial results

• Sales: CHF 31.8 million (up 148% compared to the first half of 2023).

• Net loss: CHF 211,000 (loss reduced by 96% from the first half of 2023).

• Loss of CHF 0.01 per share (improvement compared to loss of CHF 0.14 in the first half of 2023).

All figures shown in the graph above refer to the last 12 months (TTM)

Kuros Biosciences shares rose 2.5% compared to the previous week.

Risk analysis

There are still risks to consider, for example – Kuros Biosciences has 3 warning signs (and 2 that shouldn’t be ignored) that we think you should know about.

Do you have feedback on this article? Are you concerned about the content? Contact us directly from us. Alternatively, send an email to editorial-team (at) simplywallst.com.

This Simply Wall St article is of a general nature. We comment solely on the basis of historical data and analyst forecasts, using an unbiased methodology. Our articles do not constitute financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide you with long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St does not hold any of the stocks mentioned.